

Supplementary Table 1 Pathological and Biological Features of Primary PDAC Cell Lines from Patient-Derived Xenograft Tumors*

PDAC Cell lines	Patient age & gender	Tumor size & stage	Lymphatic invasion	Morphology of cell lines	Doubling time (h)	RON expression	Endocytosis of RON (EC ₅₀ = h)	Sensitivity to ADC (μg/ml)	Growth in athymic mice
AMC-01	66 & M	3.5 & IIA	Yes	epithelial-like	68	++++	Not done	2.13 ± 0.25	Not observed
AMC-02	30 & M	2.1 & IIA	No	epithelial-like	87	++++	14.3 ± 0.76	1.98 ± 0.33	Able to grow
AMC-04	53 & M	3.1 & IIB	No	mesenchymal-like	48	++	15.2 ± 0.54	5.88 ± 1.14	Able to grow
AMC-05	70 & M	5.7 & IIA	Yes	epithelial-like	75	+++	ND	2.81 ± 0.78	Not done
PDC110621	66 & M	3.5 & IIA	Yes	epithelial-like	ND	++	31.28 ± 0.47	3.51 ± 0.44	Able to grow
PDC115026	70 & M	5.7 & IIB	Yes	epithelial-like	ND	+++	36.78 ± 0.32	8.42 ± 1.12	Not done
SNU2491	61 & F	2.5 & IIB	Yes	epithelial-like	64	+++	20.25 ± 0.35	1.75 ± 0.40	Able to grow
SNU410	53 & M	NA & V	No	mesenchymal-like	72	+	Not observed	10.31 ± 1.87	Able to grow

*Primary cell lines from PDXs of PDAC patients were generated and characterized as detailed in a previous report (Jung et al., 2016). Levels of RON expression by individual cell lines were determined using immunofluorescence and Western blot analyses. H-Zt/g4 was used as the primary antibody. H-Zt/g4-induced RON endocytosis was performed using the method detailed in Experimental Procedures. Sensitivity of individual cell lines to H-Zt/g4-MMAE-induced reduction in cell viability was performed using the MTS assay as described previously [31]. Individual cell lines having capable of growing in athymic nude mice were selected for *in vivo* H-Zt/g4-MMAE therapeutic study.

Supplementary Table 2 Adverse Effects of H-Zt/g4-MMAE on blood leukocyte and erythrocytes in Cynomolgus monkey

Measurement of blood cells	Treatment with ADC	Dynamic changes of leukocytes and erythrocytes after H-Zt/g4-MMAE injection (days, Mean \pm SD)						
		0	2	4	8	15	22	29
Total leukocytes (10^9 /liter)	Control	10.37 \pm	13.35 \pm	12.94 \pm	12.35 \pm	14.33 \pm	12.12 \pm	13.15 \pm
	10 mg/kg	12.29 \pm 3.30	12.98 \pm 6.16	11.47 \pm 5.48	7.77 \pm 4.64	14.23 \pm 4.80	24.00 \pm 12.63	12.62 \pm 8.21
	30 mg/kg	13.15 \pm 6.82	11.90 \pm 2.18	12.11 \pm 2.05	2.21 \pm 0.57	34.11 \pm 12.90	16.68 \pm 5.68	11.71 \pm 0.85
Total neutrophils (10^9 /liter)	Control	3.93 \pm	10.88 \pm	4.27 \pm	4.70 \pm	5.24 \pm	3.71 \pm	4.68 \pm
	10 mg/kg	5.77 \pm 2.64	5.12 \pm 1.97	3.70 \pm 1.14	1.50 \pm 0.86	2.18 \pm 2.69	11.70 \pm 5.53	7.85 \pm 2.81
	30 mg/kg	7.34 \pm 6.70	6.58 \pm 2.07	7.89 \pm 2.14	0.04 \pm 0.03	28.18 \pm 4.65	8.03 \pm 3.63	7.08 \pm 0.13
Total lymphocytes (10^9 /liter)	Control	5.60 \pm	5.43 \pm	7.83 \pm	6.67 \pm	7.90 \pm	7.18 \pm	7.31 \pm
	10 mg/kg	6.32 \pm 3.98	7.12 \pm 3.83	7.25 \pm 4.79	5.79 \pm 3.75	10.19 \pm 3.83	10.83 \pm 6.57	7.92 \pm 4.99
	30 mg/kg	6.20 \pm 1.07	4.55 \pm 1.71	3.79 \pm 0.88	2.08 \pm 0.57	14.32 \pm 4.23	7.42 \pm 1.76	7.45 \pm 1.23
Total monocytes (10^9 /liter)	Control	0.87 \pm	0.81 \pm	0.74 \pm	0.91 \pm	1.07 \pm	1.10 \pm	0.93 \pm
	10 mg/kg	0.73 \pm 0.27	0.66 \pm 0.39	0.41 \pm 0.27	0.36 \pm 0.15	2.01 \pm 2.35	1.41 \pm 1.53	0.61 \pm 0.35
	30 mg/kg	0.75 \pm 0.08	0.78 \pm 0.32	0.32 \pm 0.14	0.08 \pm 0.03	7.96 \pm 4.72	1.20 \pm 0.48	0.82 \pm 0.36
Neutrophil (%)	Control	36.9 \pm	38.1 \pm	33.5 \pm	37.1 \pm	36.6 \pm	34.4 \pm	35.9 \pm
	10 mg/kg	47.4 \pm 28.2	40.9 \pm 4.7	37.3 \pm 21.7	22.0 \pm 10.4	20.5 \pm 25.7	52.4 \pm 16.2	40.8 \pm 7.7
	30 mg/kg	49.1 \pm 20.1	55.1 \pm 12.4	34.6 \pm 8.2	2.0 \pm 1.6	62.5 \pm 21.8	46.9 \pm 5.7	52.4 \pm 0.4
Lymphocyte (%)	Control	55.3 \pm	53.0 \pm	60.0 \pm	54.8 \pm	55.1 \pm	59.4 \pm	55.7 \pm
	10 mg/kg	49.4 \pm 25.8	54.6 \pm 3.8	58.6 \pm 20.1	71.2 \pm 11.9	71.5 \pm 17.2	42.8 \pm 14.2	62.6 \pm 7.0
	30 mg/kg	45.3 \pm 17.9	37.6 \pm 12.2	31.9 \pm 9.0	94.1 \pm 2.5	66.5 \pm 5.3	55.7 \pm 6.6	63.3 \pm 6.4
Monocyte (%)	Control	7.2 \pm	6.8 \pm	7.1 \pm	7.6 \pm	7.4 \pm	8.2 \pm	6.8 \pm
	10 mg/kg	3.0 \pm 2.4	5.0 \pm 2.3	3.4 \pm 1.1	5.1 \pm 1.1	11.8 \pm 10.6	4.6 \pm 3.8	5.0 \pm 1.7
	30 mg/kg	4.2 \pm 1.4	6.4 \pm 1.7	2.6 \pm 0.6	3.8 \pm 1.3	14.6 \pm 9.1	7.2 \pm 2.3	7.1 \pm 3.6
Total erythrocytes (10^{12} /liter)	Control	5.44 \pm	4.83 \pm	4.69 \pm	4.68 \pm	4.98 \pm	5.03 \pm	5.24 \pm
	10 mg/kg	5.58 \pm 0.34	5.03 \pm 0.25	4.72 \pm 0.30	4.21 \pm 0.26	5.04 \pm 0.06	5.06 \pm 0.07	4.96 \pm 0.16
	30 mg/kg	5.34 \pm 0.56	4.93 \pm 0.38	4.64 \pm 0.6	3.95 \pm 0.26	3.59 \pm 0.08	4.00 \pm 0.12	4.73 \pm 0.22
Total reticulocytes (10^9 /liter)	Control	61.7 \pm	55.7 \pm	63.5 \pm	67.2 \pm	72.0 \pm	63.0 \pm	71.1 \pm
	10 mg/kg	72.8 \pm 12.6	66.5 \pm 22.2	65.0 \pm 28.5	42.0 \pm 10.3	379.3 \pm 165.6	147.0 \pm 66.0	145.7 \pm 50.6
	30 mg/kg	59.6 \pm 6.9	51.1 \pm 11.8	23.5 \pm 7.5	28.7 \pm 12.0	146.1 \pm 31.1	289.0 \pm 102.3	130.8 \pm 61.7

Supplementary Table 3 Effect of H-Zt/g4-MMAE *in vivo* on various enzymatic activities in blood samples collected from cynomolgus monkeys

Measurement of Blood Cells	Treatment with ADC	Dynamic changes of blood Enzymatic levels after H-Zt/g4-MMAE injection (days, Mean \pm SD)							Clinical implications
		0	2	4	8	15	22	29	
Alanine transaminase (ALT, Unit/L)	Control	42 \pm	43 \pm	44 \pm	63 \pm	52 \pm	38 \pm	40 \pm	Liver damage
	10 mg/kg	57 \pm 19	110 \pm 39	127 \pm 34	86 \pm 25	56 \pm 13	57 \pm 8	53 \pm 18	
	30 mg/kg	45 \pm 22	79 \pm 40	122 \pm 67	95 \pm 35	40 \pm 11	34 \pm 9	34 \pm 11	
Alkaline phosphatase (ALP, Unit/L)	Control	297 \pm	357 \pm	367 \pm	456 \pm	428 \pm	362 \pm	392 \pm	Liver damage or bone disorder
	10 mg/kg	413 \pm 53	353 \pm 37	384 \pm 46	510 \pm 22	517 \pm 15	462 \pm 49	429 \pm 31	
	30 mg/kg	352 \pm 129	311 \pm 96	339 \pm 117	486 \pm 224	629 \pm 357	428 \pm 159	444 \pm 174	
Aspartate transaminase (AST, Unit/L)	Control	55 \pm	62 \pm	88 \pm	69 \pm	41 \pm	38 \pm	42 \pm	Liver or heart damage
	10 mg/kg	46 \pm 9	135 \pm 65	96 \pm 10	75 \pm 12	53 \pm 3	49 \pm 8	42 \pm 7	
	30 mg/kg	58 \pm 31	255 \pm 125	394 \pm 254	171 \pm 98	64 \pm 8	51 \pm 8	50 \pm 12	
Gamma-glutamine transaminase (γ -GT, Unit/L)	Control	54 \pm	39 \pm	38 \pm	42 \pm	44 \pm	40 \pm	44 \pm	Liver damage
	10 mg/kg	52 \pm 9	50 \pm 14	49 \pm 16	49 \pm 15	48 \pm 17	51 \pm 15	52 \pm 17	
	30 mg/kg	44 \pm 18	42 \pm 18	40 \pm 19	35 \pm 6	44 \pm 17	43 \pm 19	41 \pm 18	
Lactate dehydrogenase (LDH, Unit/L)	Control	342 \pm	312 \pm	335 \pm	425 \pm	414 \pm	297 \pm	350 \pm	Various tissue damage
	10 mg/kg	338 \pm 85	875 \pm 159	745 \pm 184	801 \pm 290	700 \pm 122	373 \pm 30	349 \pm 104	
	30 mg/kg	412 \pm 27	1360 \pm 396	1,694 \pm 820	1,073 \pm 206	1,364 \pm 543	727 \pm 294	534 \pm 170	
Creatine kinase (CPK, Unit/L)	Control	171 \pm	156 \pm	148 \pm	151 \pm	171 \pm	169 \pm	176 \pm	Muscle damage
	10 mg/kg	167 \pm 27	656 \pm 366	1,413 \pm 180	268 \pm 35	238 \pm 29	198 \pm 18	174 \pm 15	
	30 mg/kg	183 \pm 39	530 \pm 306	7,734 \pm 562	861 \pm 565	208 \pm 102	169 \pm 21	186 \pm 35	